Skip to main content
Triangle logo TriangleGet started

Prednisone (NCT06045247)

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma: a one-minute explainerNCT060452471 min

Prednisone trial for Large B-cell Lymphoma (NCT06045247). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated diffuse large B-cell, high-grade B-cell or T-cell/histiocyte-rich large B-cell lymphoma who cannot receive anthracycline chemotherapy. Disease must be bulky stage II, stage III or stage IV.

The idea: add epcoritamab injections to rituximab, cyclophosphamide, vincristine and prednisone. Epcoritamab connects T cells to CD20-positive lymphoma cells to trigger immune attack. It starts in cycle two. R-miniCVP lasts up to six cycles; epcoritamab can continue through cycle twelve. Researchers assess response and safety.

This phase 2 study plans 40 patients. Dai Chihara leads MD Anderson's recruiting Houston site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.